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Direct neurotransmitter activation of voltage-gated
potassium channels
Rían W. Manville1, Maria Papanikolaou1 & Geoffrey W. Abbott1
Voltage-gated potassium channels KCNQ2–5 generate the M-current, which controls neu-
ronal excitability. KCNQ2–5 subunits each harbor a high-afﬁnity anticonvulsant drug-binding
pocket containing an essential tryptophan (W265 in human KCNQ3) conserved for >500
million years, yet lacking a known physiological function. Here, phylogenetic analysis, elec-
trostatic potential mapping, in silico docking, electrophysiology, and radioligand binding
assays reveal that the anticonvulsant binding pocket evolved to accommodate endogenous
neurotransmitters including γ-aminobutyric acid (GABA), which directly activates KCNQ5
and KCNQ3 via W265. GABA, and endogenous metabolites β-hydroxybutyric acid (BHB) and
γ-amino-β-hydroxybutyric acid (GABOB), competitively and differentially shift the voltage
dependence of KCNQ3 activation. Our results uncover a novel paradigm: direct neuro-
transmitter activation of voltage-gated ion channels, enabling chemosensing of the neuro-
transmitter/metabolite landscape to regulate channel activity and cellular excitability.
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+ efﬂux is the primary force behind the cellular repolar-
ization that ends action potentials, and is also important in
setting and maintaining resting membrane potential, and
preventing aberrant action potential ﬁring. In vertebrate nervous
systems, the M-current, a muscarinic-inhibited Kv current1
generated by KCNQ (Kv7) family Kv channels (M-channels)2, 3,
is the predominant Kv current regulating neuronal excitability4.
KCNQ channels, like all other known Kv channels, form as tet-
ramers of α subunits, each subunit of which contains six trans-
membrane (S) segments, split into the voltage-sensing domain
(VSD, S1–4) and the pore module (S5–6). The M-current is
generated primarily by KCNQ2 and KCNQ3 subunits, most
commonly in the form of heteromeric (KCNQ2/3) channels4, but
homomers also exist in vivo and KCNQ4 and KCNQ5 also
contribute5; KCNQ5, for example, generates hippocampal after-
hyperpolarization currents6. Because KCNQ2/3 channels are
receptor-regulated, non-inactivating, and open at relatively
hyperpolarized membrane potentials, they are uniquely suited to
regulate neuronal excitability, and their gating state dictates
phasic versus tonic ﬁring of neurons4.
KCNQ2 subunits are particularly enriched in GABAergic
neurons, especially those important for control of network
oscillations and synchrony7. Presynaptic KCNQ2/3 channels are
thought to modulate glutamate and γ-aminobutyric acid (GABA)
release, and are suggested to act pre- and post-synaptically to
suppress neuronal excitability8, 9, and Kcnq2-deﬁcient mice
exhibit abnormal GABAergic synaptic transmission10.
KCNQ2–5 are therapeutically activated by a class of antic-
onvulsants typiﬁed by retigabine and ML-213, which facilitate
channel opening at more negative membrane potentials.
KCNQ3 is the most sensitive to retigabine11, although
KCNQ2–5 all contain a transmembrane segment 5 (S5) tryp-
tophan (W265 in human KCNQ3, W270 in KCNQ5) that is
essential for sensitivity to this class of anticonvulsants12, yet has
no known physiological role. Here, phylogenetic analysis
revealed that W265/270 is highly conserved, for >500 million
years in deuterostomes, and is also present in some Cnidaria,
e.g., Hydrozoans. In contrast, W265/270 was absent from all
protostome KCNQs we analyzed (Fig. 1a–c). Given this
enduring conservation, we hypothesized that W265/270
evolved as a chemosensor for native ligands present in both
primitive and modern nervous systems. Here, we show that
KCNQ3-W265 forms part of a high-afﬁnity binding site for the
neurotransmitter GABA and related metabolites, binding of
which potentiates channel activation especially at subthreshold
potentials, resulting in membrane hyperpolarization. This ﬁrst
description of direct activation of voltage-dependent ion
channels by a neurotransmitter uncovers a novel mechanism
for controlling cellular excitability.
Results
KCNQ2-5 channels contain GABA binding sites. Focusing on
chemical properties required for anticonvulsant action of retiga-
bine and related compounds on KCNQ2/3, including negative
electrostatic surface potential localized close to a carbonyl oxy-
gen13, we identiﬁed GABA as a candidate. GABA, the primary
inhibitory neurotransmitter, bears strong negative electrostatic
surface potential near its carbonyl oxygen, in contrast to the
chemically related excitatory neurotransmitter, glutamate
(Fig. 1d). Strikingly, in silico docking predicted binding of GABA
to KCNQ3-W265, similar to retigabine and ML-213 (Fig. 1e).
GABA does not readily cross the plasma membrane, but W265
lies in a crevice apparently accessible from the extracellular side
(Fig. 1f); this portion of S5 also appeared accessible in the related
Kv1.2–Kv2.1 “paddle-chimera” structure, which includes lipids14
(Fig. 1g). Accordingly, Xenopus oocyte expressed homomeric
wild-type human KCNQ2–5-bound extracellularly applied 3H-
GABA, while KCNQ1, which lacks W265, did not (Fig. 1h;
Supplementary Fig. 1). Further indicative of the speciﬁcity of 3H-
GABA binding to KCNQ2–5, non-injected oocytes bound mini-
mal 3H-GABA (Supplementary Fig. 1) and 3H-GABA binding to
homomeric wild-type human KCNQ3 was outcompeted by co-
incubation with cold (unlabeled) GABA (1 mM) (Fig. 1i). Finally,
results of saturation binding experiments conducted with oocyte-
expressed homomeric wild-type human KCNQ3 using 10 dif-
ferent concentrations of 3H-GABA were consistent with binding
to a speciﬁc site in KCNQ3 with a Kd of 126 nM and a Bmax of 27
fmol per oocyte (Fig. 1j; see Supplementary Fig. 1d for an
expanded view of the low [GABA] portion of the curve). The
Bmax value was similar to results obtained from previous intact
oocyte radioligand binding studies of other heterologously
expressed membrane proteins15.
GABA activates KCNQ3 and KCNQ5. Using oocyte expression
and two-electrode voltage clamp (TEVC), we found that GABA
activates KCNQ3* (an expression-optimized KCNQ3-A315T
mutant that ensures robust currents16) and KCNQ5, especially at
subthreshold potentials. In contrast, the activity of KCNQ1, 2 and
4 was relatively GABA-insensitive (Fig. 2a; Supplementary Fig-
ures 2–6; Supplementary Tables 1–5). Thus, the KCNQ3-W265
equivalent is important for GABA binding (Fig. 1) but not suf-
ﬁcient for KCNQ activation by GABA (Fig. 2a). The KCNQ3*
GABA EC50 was 1.0 ± 0.1 µM at −60 mV (Supplementary
Table 9), a higher sensitivity than that previously reported for
retigabine (11.6 µM) or ML-213 (3.6 µM)13. This was a lower
potency than the Kd we observed for GABA binding to wild-type
KCNQ3 (126 nM; Fig. 1j); but see GABA effects on KCNQ2/3-
dependent membrane hyperpolarization, below (Fig. 2h). GABA
(10 µM) shifted the V0.5 of activation of KCNQ3* by −8 mV, but
this understates the efﬁcacy of GABA in the activation of
KCNQ3*, because there is also a general increase in channel
activity across the voltage range from −60mV to +20 mV
(Fig. 2a, b; Supplementary Fig. 4). The KCNQ5 GABA EC50 was
0.06 ± 0.01 µM at −60 mV, a 17-fold higher GABA sensitivity
than for KCNQ3* (Supplementary Table 9), but the efﬁcacy of
GABA with respect to channel activation was more than threefold
greater for KCNQ3* compared to KCNQ5 (Fig. 2a, b). GABA (10
µM) shifted the KCNQ5 V0.5 of activation by −15 mV (Supple-
mentary Figure 6; Supplementary Table 5).
GABA activation of KCNQ2/3 channels. We next focused on
heteromeric KCNQ2/3 channels, the primary molecular correlate
of neuronal M-current4. GABA activated KCNQ2/3 with
increasing efﬁcacy at more negative membrane potentials, a
property important for subduing neuronal activity; thus GABA
(10 µM) negative-shifted the V0.5 of KCNQ2/3 activation by −14
mV (Fig. 2c–e; Supplementary Fig. 7; Supplementary Table 6). At
−60 mV, 10 µM GABA increased KCNQ2/3 current fourfold
(Fig. 2f). The EC50 for KCNQ2/3 activation was 0.85 ± 0.1 µM
GABA at −60 mV (Supplementary Table 9), while the excitatory
neurotransmitter glutamate had no effect on KCNQ2/3 even at
10 mM (Fig. 2g; Supplementary Fig. 8; Supplementary Table 7).
Reﬂecting its greater efﬁcacy at more negative membrane
potentials and the efﬁciency of KCNQ channels in setting
membrane potential (EM), GABA exerted potent effects on
KCNQ2/3-dependent membrane hyperpolarization (EC50, 120
nM) (Fig. 2h). Canonical pentameric GABAA receptors, which
are triggered to open when GABA binds to an extracellularly
located, inter-subunit GABA-binding site, participate in either
phasic or tonic inhibition, depending on their location and
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subunit composition17, 18. Tonic extracellular GABA concentra-
tion in mammalian brain is calculated to be ~160 nM19, 20, and
transient peak GABA concentrations of several millimolar occur
in the synaptic cleft21. Canonical αxβ3γ2 GABAARs exhibit GABA
EC50 values of 1.0–157 µM22, 23. Thus, KCNQ2/3 channel GABA
afﬁnity compares to that of the most sensitive αxβ3γ2 GABAARs.
GABA begins to activate KCNQ2/3 immediately on wash-in; the
current augmentation takes ~3 min to plateau, and persists
during wash-out (Fig. 2i). Time to onset of functional effects
upon wash-in did not appear voltage-dependent, as it was not
altered by switching to +60 mV during wash-in; the GABA-
augmented current was readily inhibited by washing in the
KCNQ channel inhibitor, XE991 (50 µM) (Fig. 2j). GABA
accelerated KCNQ2/3 activation and slowed deactivation, sug-
gesting GABA stabilizes the KCNQ2/3 open state (Fig. 2k; Sup-
plementary Fig. 9; Supplementary Table 8).
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GABA activates KCNQ2/3 channels by binding to KCNQ3-
W265. Our radioligand binding data (Fig. 1h–j) demonstrate
direct binding of GABA to KCNQ2–5, but we nevertheless tested
for other possibilities and artifacts. At 100 µM, GABA neither
induced current in, nor shifted the resting membrane potential of,
water-injected oocytes, demonstrating our observations did not
arise from an endogenous ion channel (Fig. 3a), neither did
increasing GABA to 1 mM produce any noticeable effects (Sup-
plementary Fig. 10). Neither did GABA, even at 1 mM, affect
activity of KCNA1 (Kv1.1), a Kv channel from a different sub-
family (Fig. 3b; Supplementary Fig. 11; Supplementary Table 10).
GABAB receptors are metabotropic receptors that can activate
some potassium channels via pertussis-sensitive G proteins24. In
previous studies, it was concluded that Xenopus oocytes do not
express endogenous GABAB receptors25, which can activate some
potassium channel subtypes (not reported for KCNQs), but we
nevertheless tested for their possible role in the observed effects,
using four approaches. These studies ruled out a role for GABAB
receptors in KCNQ activation by GABA, as follows. First, GABA
activated KCNQ2/3 even after overnight treatment of oocytes
with pertussis toxin, which inhibits G proteins associated with
GABAB activation of some potassium channels (Fig. 3c; Supple-
mentary Fig. 12; Supplementary Table 11). Second, KCNQ2/3
channels were insensitive to baclofen (100 µM), a GABA analog
that acts as a GABABR agonist26 (Fig. 3d; Supplementary Fig. 13;
Supplementary Table 12). Third, GABAB receptor antagonist
saclofen neither altered KCNQ2/3 currents alone, nor did it
diminish GABA activation of KCNQ2/3 (Fig. 3e; Supplementary
Figs. 14, 15; Supplementary Tables 13, 14). Fourth, the potent
GABAB receptor antagonist CGP55845 neither altered KCNQ2/3
currents alone, nor did it diminish GABA activation of KCNQ2/3
(Fig. 3f; Supplementary Figs. 16, 17; Supplementary Tables 15,
16).
Mutagenesis studies further cemented the conclusion that
GABA directly modulates KCNQ2/3 channels. Reﬂecting our in
silico predictions, 3H-GABA binding results (Fig. 1e–j), and
KCNQ2 GABA-insensitivity (Fig. 2a), a mutant KCNQ2/3
channel complex in which the essential KCNQ3 tryptophan
was replaced with leucine (KCNQ2/KCNQ3-W265L) was GABA-
insensitive (up to 10 mM), as was double tryptophan-mutant
heteromer KCNQ2-W236L/KCNQ3-W265L (Fig. 3g–i; Supple-
mentary Figs. 18, 19; Supplementary Table 17), which also
showed impaired 3H-GABA binding (Fig. 3j).
GABA activates endogenous neuronal M-channels. Switching to
mammalian cells, KCNQ2/3 channels heterologously expressed in
Chinese hamster ovary (CHO) cells were likewise activated by
GABA, demonstrating this was not an oocyte-speciﬁc phenom-
enon (Fig. 4a, b). GABA (100 µM) shifted the midpoint voltage
dependence of KCNQ2/3 activation by −14.6 mV (from −2.9 to
−17.5 mV, Supplementary Table 18), similar to the shift we
observed in oocytes (−14 mV; Fig. 2c and Supplementary
Table 6).
We next tested the effected of GABA on native M-current in
PC12 cells, a rat pheochromocytoma cell line of neural crest
origin that retains many of the properties of dopaminergic
neurons and has previously been used to study M-current27, 28.
Culturing PC12 cells for 4–7 days with NGF resulted in extensive
neurite outgrowth and increased expression of native voltage-
gated potassium currents (Fig. 4c), as previously reported27, 28.
We found that 8/10 PC12 cells studied expressed potassium
current sensitive to the KCNQ channel blocker XE991 (10 µM).
Importantly, in seven of these eight cells, GABA (100 µM)
negative-shifted the voltage dependence of the PC12 cell tail
current activation, in the presence of picrotoxin and CGP55845
to block native canonical GABAA and GABAB receptors,
respectively. The mean shift of −13.5 mV in the midpoint of
voltage-dependent activation in PC12 cells in response to 100 µM
GABA, in the presence of canonical GABAR blockers (Supple-
mentary Table 19), was similar to that for KCNQ2/3 channels
expressed in oocytes and in CHO cells (−14 mV) with 100 µM
GABA application. Application of KCNQ channel blocker XE991
(10 µM) removed the GABA-dependent negative-shift in the
PC12 cell tail currents (Fig. 4d).
We also recorded the effects of GABA on dorsal root ganglion
(DRG) neurons isolated from adult mice, using perforated patch-
clamp whole-cell recordings. Cells were held at −20 mV to
inactivate other Kv channels and then pulsed to −60 mV, after
wash-in of inhibitors of canonical GABAA and GABAB receptors
(100–300 µM picrotoxin; 10 µM CGP55845, respectively), ﬁrst in
the absence, and then in the presence, of GABA (100 µM). XE991
(10 µM) was subsequently washed in, in the presence of the other
drugs, to inhibit M-current. From a holding potential of −20 mV,
pulses to −60 mV produced a partial deactivation and then
stabilization characteristic of M-current; current at −60mV was
increased by GABA and this current was decreased by XE991
(Fig. 4e). GABA (100 µM) increased the relative proportion of
−60 mV current to that of −20 mV current, consistent with
greater GABA efﬁcacy at more negative voltages (Fig. 4f).
Accordingly, the mean GABA-dependent current increase was
threefold at −60 mV, but there was no mean change in current at
−20 mV (Fig. 4g). We also quantiﬁed the deactivating portion of
the −60 mV current in isolation. GABA decreased this deactivat-
ing current by ~25%, consistent with fewer channels closing upon
the transition from −20 mV to −60 mV, in the presence of
Fig. 1 Neuronal KCNQs contain an evolutionarily conserved GABA-binding pocket. a Sequence alignment of S5 residues 265–275 (human numbering) in
KCNQ5 or the closest equivalent in representative organisms from the clades shown in b. Yellow, tryptophan essential for drug binding (KCNQ5-W270;
KCNQ3-W265). Organism descriptors: black, single KCNQ gene in genome, no W270 equivalent; dark blue, multiple KCNQ genes, no W270 equivalent;
red, multiple KCNQ genes, at least one containing W270 equivalent. b Phylogeny (distances not intended to equate to time) indicating evolutionary
relationships from ancestral Protista to Chordates and other major clades. Text colors as in a; gray, no KCNQ genes. c Upper, chimeric KCNQ1/
KCNQ3 structural model (red, KCNQ3-W265; cyan, KCNQ3-L314); lower, topological representation (pentagon, KCNQ3-W265). d Electrostatic surface
potentials (red, electron-dense; blue, electron-poor; green, neutral) and structures calculated and plotted using Jmol. e Close-up side views of KCNQ
structure as in c, showing results of SwissDock unguided in silico docking of GABA, retigabine, and ML-213. f View from extracellular side of KCNQ
structure showing W265 accessibility. g View from extracellular side of Kv1.2-Kv2.1 “paddle-chimera” structure showing S5 accessibility (*) despite lipid
presence (lipid spaceﬁlls shown). h Mean 3H-GABA binding, normalized to channel surface expression, for KCNQ channels expressed in Xenopus oocytes;
n= 47 (Q1), 14 (Q2), 48 (Q3), 30 (Q4), 44 (Q5) in two to four batches of oocytes; ***P= 0.0003; ****P < 0.0001; versus KCNQ1. Inset, sequence
alignment of S5 265–275 (KCNQ5 numbering) for human KCNQ1–5. Yellow, KCNQ5-W270. Error bars indicate SEM. iMean 3H-GABA binding to KCNQ3
expressed in Xenopus oocytes, with (+) versus without (−) competition from unlabeled (cold) GABA (1 mM); n= 20 per group; **P= 0.007. Error bars
indicate SEM. j Saturation binding studies using 3H-GABA and oocyte-expressed KCNQ3. Ten different 3H-GABA concentrations were used (0.1–1000 nM;
n= 20 oocytes per group). Mean non-speciﬁc binding was quantiﬁed in parallel experiments similar except for the addition of 1 mM cold GABA. Mean
speciﬁc binding was calculated by subtracting mean non-speciﬁc from total binding. Error bars indicate SEM
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GABA. XE991 applied in combination with GABA inhibited this
deactivating current >50%, consistent with the majority of the
current being passed by KCNQ channels (Fig. 4h). Thus, GABA
activation of M-channels is direct, independent of the expression
system, and occurs with both exogenously and endogenously
expressed channels.
GABA overcomes muscarinic inhibition of KCNQ2/3 channels.
Muscarinic inhibition of KCNQ channels is achieved by disrup-
tion of KCNQ regulation by phosphatidylinositol 4,5-bispho-
sphate (PIP2). PIP2 facilitates KCNQ channel opening, thus
hyperpolarizing KCNQ channel voltage-dependent activation,
enabling opening at more negative membrane potentials. Mus-
carinic acetylcholine receptor (mAChR) activation disrupts this,
by hydrolyzing PIP2 and/or by reducing PIP2 sensitivity, thus
positive-shifting KCNQ channel voltage dependence of activa-
tion, inhibiting activity particularly at negative potentials29. The
lack of GABA responsiveness of KCNQ1, 2, and 4 (Fig. 2a)
effectively ruled out the possibility that endogenous mAChRs/
changes in PIP2 were mediating GABA effects on KCNQ3.
However, we further tested this and also asked whether GABA
could overcome muscarinic inhibition of KCNQ2/3. For these
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experiments, we reverted to the Xenopus oocyte expression sys-
tem. As expected, application of acetylcholine (ACh) to activate
endogenous oocyte mAChRs inhibited KCNQ2/3 activity, espe-
cially at negative voltages; maximal effect occurred at 1 µM ACh
and higher (Fig. 5a, b; Supplementary Fig. 20; Supplementary
Table 20). For comparison, application of a 100-fold greater
concentration of dopamine (100 µM) had no effect on KCNQ2/3
current (Fig. 5c; Supplementary Fig. 21; Supplementary Table 21).
ACh inhibition of KCNQ2/3 was prevented by the mAChR
antagonist atropine, indicating that ACh inhibited KCNQ2/
3 solely by the canonical, indirect pathway requiring mAChR
activation (Fig. 5b, d; Supplementary Fig. 22). Atropine itself had
no direct effect on KCNQ2/3 activity (Fig. 5b, e; Supplementary
Fig. 23; Supplementary Table 22). Additionally, atropine did not
inhibit GABA activation of KCNQ2/3 (Fig. 5f; Supplementary
Fig. 24; Supplementary Table 23), ruling out an indirect, mAChR-
dependent mechanism for GABA activation of KCNQ2/3, as
expected from the GABA-insensitivity of other PIP2-sensitive
KCNQs (Fig. 2a).
Importantly, GABA overcame ACh-dependent KCNQ2/3
inhibition (Fig. 5g; Supplementary Fig. 25; Supplementary
Table 24), indicating that GABA can override the canonical
muscarinic inhibition of KCNQ2/3 for which the M-current is
named. To further test this conclusion, we pre-incubated
KCNQ2/3-expressing oocytes with the phosphoinositide 3/4-
kinase inhibitor, wortmannin (30 µM for 3 h), to prevent PIP2
synthesis and partially deplete intracellular PIP2. Under these
conditions, KCNQ2/3 was still robustly activated by GABA,
which now (at 10 µM) shifted the V0.5 of KCNQ2/3 activation by
−24 mV (Fig. 5h; Supplementary Fig. 26; Supplementary
Table 25). Thus, GABA activation of KCNQ2/3 can overcome
the inhibitory effects of mAChR activation or direct PIP2
depletion/prevention of PIP2 synthesis. As a ﬁnal control for
the independence of GABA from mAChR regulation, we
examined effects of GABA on KCNQ1-KCNE1, a heteromeric
channel with 100-fold higher PIP2 sensitivity than homomeric
KCNQ130. We found no effect of GABA on KCNQ1-KCNE1
activity, nor on the resting membrane potential of KCNQ1-
KCNE1-expressing oocytes (Fig. 5i, j; Supplementary Fig. 27;
Supplementary Table 26). Thus, KCNQ activation by GABA does
not involve mAChRs or PIP2, and indeed can overcome these
factors in KCNQ2/3 channels.
GABA analogs compete for KCNQ3-W265 binding. GABA
coexists in the CNS with various analogs and metabolites, two of
which, β-hydroxybutyrate (BHB) and γ-amino-β-
hydroxybutyrate (GABOB), we discovered to also activate
KCNQ2/3. GABOB had a higher afﬁnity (EC50 of 0.12 µM), but
was a lower efﬁcacy partial agonist, for KCNQ2/3 compared to
BHB (EC50 of 0.94 µM) and to GABA (EC50 of 0.85 µM). In
contrast, the structurally related straight-chain alkyl carboxylic
acid, valeric acid, was inactive up to 5 mM (Fig. 6a, b; Supple-
mentary Figs. 28–30; Supplementary Tables 27–29). The high
sensitivity of KCNQ2/3 for BHB is in contrast with that of
canonical GABAA receptors, which are BHB-insensitive up to 5
mM BHB31. In silico docking studies suggested that, like GABA,
BHB, and GABOB bind to KCNQ3-W265 (Fig. 6c). Accordingly,
GABOB, a higher-afﬁnity partial agonist compared to GABA,
diminished the KCNQ2/3-activating efﬁcacy of GABA (Fig. 6d;
Supplementary Fig. 31; Supplementary Table 30). In contrast and
as expected, glutamate, which we found to be inactive on
KCNQ2/3 (Fig. 2g), did not alter GABA activation of KCNQ2/3
(Fig. 6e; Supplementary Fig. 32; Supplementary Table 31). Finally,
we found that GABOB reduces the efﬁcacy of retigabine, an
anticonvulsant that also activates KCNQ2/3 by binding to the
W265 equivalent (Fig. 6f).
Discussion
Prior phylogenetic analyses of KCNQ sequences showed their
absence in Porifera (sponges) and ctenophores, and suggested
that KCNQ emerged as a single gene in a cnidarian/bilaterian
ancestor. The KCNQ encoded by this single gene evolved PIP2
sensitivity even before the Bilaterian/Cnidarian divergence, indi-
cating the importance of this feature as early as 600 million years
ago32. This PIP2 sensitivity developed before the duplication of
KCNQ into genes orthologous to present-day KCNQ1 and
KCNQ5, creating multiple KCNQ genes per genome. Some cni-
darians, including Hydra (a Hydrozoan) have multiple KCNQ
genes, whereas others, such as Nematostella (an Anthozoan) have
only one. Previous phylogenetic analysis suggested that cnidarian
KCNQs do not ﬁt into either of the KCNQ clades present in
bilaterian genomes, which are split into KCNQ1-like and
KCNQ2-like32. As protostome KCNQs lack the W270 equivalent
(Fig. 1a, b), it is interesting to ponder whether cnidarian KCNQs
evolved the S5 W independently to the deuterostomes, or whether
protostomes lost a W already present in a cnidarian/bilaterian
ancestor. Either way, this places emergence of KCNQ5-W270 or
its equivalent much earlier than evolution of the anchor motif for
interaction with Ankyrin G, required for location at axon initial
segments, which appeared in KCNQs in the time period of
divergence of extant jawless and jawed vertebrates33. For com-
parison, Hydra are also known to express functional canonical
GABAA receptors with pharmacology similar in some respect to
mammalian GABAA receptors34. GABA itself is found in all
organisms; glutamate decarboxylase (GAD), which catalyzes
conversion of glutamate into GABA, is found in bacteria (where
Fig. 2 KCNQ3 and KCNQ5 are activated by GABA in Xenopus oocytes. All error bars in ﬁgure indicate SEM. a Mean tail current versus prepulse voltage
relationships recorded by TEVC in Xenopus laevis oocytes expressing homomeric KCNQ1–5 channels in the absence (black) and presence (purple) of GABA
(n= 4–8). Voltage protocol as in c. bMean GABA dose response at−60mV for KCNQ1–5, quantiﬁed from data as in a (n= 5–8). c TEVC recordings using
a current-voltage family protocol (upper left inset) in oocytes expressing KCNQ2/3 channels in the absence (black) and presence (purple) of GABA (10
µM). Dashed line indicates zero current level in this and all following current traces. d Averaged current traces at −60mV for KCNQ2/3 channels in the
absence (black) and presence (purple) of GABA (10 µM) (n= 10). Voltage protocol upper inset. e Left, mean tail current; right, mean normalized tail
current (G/Gmax), both measured at arrow in voltage protocol (center) from traces as in c, with versus without GABA (10 µM) (n= 10). f Mean voltage
dependence of KCNQ2/3 current fold-increase by GABA (10 µM), plotted from traces as in c (n= 10). g Mean dose response of KCNQ2/3 channels at
−60mV for GABA (calculated EC50= 0.85 µM; n= 10) and glutamate (no effect; n= 5). h GABA hyperpolarizes resting membrane potential (EM) of
unclamped oocytes expressing KCNQ2/3. Left, effects of 10 µM GABA; right, dose response; n= 10, ****P < 0.0001. i Exemplar −60mV KCNQ2/3 current
before (left, black), during wash-in of GABA (purple) and after wash-out (right, black). j Exemplar −60mV KCNQ2/3 current before (left, black), during
wash-in of GABA (purple), wash-in of XE991 (red), and after wash-out (right, black). Membrane potential was clamped at −60mV except for a 2-min
pulse to +60mV during the early phase of GABA wash-in. k Mean activation (left) and deactivation (right) rates for KCNQ2/3 before (control) and after
wash-in of GABA (n= 10); **P < 0.01; ***P= 0.0007. Activation rate was quantiﬁed using voltage protocol as in c. Deactivation rate was quantiﬁed using
voltage protocol shown above
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decarboxylation of amino acids including glutamate aids in acid
resistance35) and plants (e.g., in soybean36) in addition to
animals.
KCNQ5-W270/KCNQ3-W265 are necessary for binding but
not sufﬁcient for GABA-dependent activation; KCNQ2 and
KCNQ4 each bear an equivalent residue and bind GABA but are
not activated by GABA, analogous to but more extreme than the
lower retigabine sensitivity of KCNQ2 versus KCNQ337. Thus,
other residues are important, for determining binding afﬁnity/
precise position and/or communicating GABA binding to the
KCNQ gating machinery. The ﬁnding that KCNQ5, the modern
KCNQ most closely related to the progenitor KCNQ found in
primitive deuterostome nervous systems, is GABA-sensitive, is
consistent with the idea that the ability to activate in response to
GABA was a positive selection pressure contributing to con-
servation of KCNQ5-W270.
This also suggests a plausible explanation for why modern,
neuronal KCNQs bear the W265 equivalent while the modern-
day cardiac and epithelial KCNQ1 subunit does not. After the
founder KCNQ gene was duplicated in early bilaterians, tens of
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millions of years later when nervous systems were centralizing in
deuterostomes, there was a positive selective pressure for the
progenitor neuronal KCNQ (most similar to mammalian
KCNQ5), but not non-neuronal KCNQ1, to sense GABA, and
KCNQ5-W270 or its equivalent emerged and is conserved in
deuterostomes to the present day. When the other neuronal
KCNQs (KCNQ2, 3 and 4) emerged, they retained the ability to
bind GABA but only one (KCNQ3) is also activated by GABA.
The functional complexity in terms of responsiveness to GABA
may help explain why several different KCNQs are present in
modern nervous systems, as the various homomeric and het-
eromeric KCNQ channels can each respond to GABA differently.
The evolution of KCNQ GABA sensitivity also paved the way for
cardiac-safe KCNQ2–5 openers, which require the tryptophan
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present in neuronal KCNQs but not cardiac-expressed KCNQ1,
to be developed by pharmaceutical companies. There are other
mechanisms for ligand-dependent opening of KCNQs, however,
as some pharmacological agents activate KCNQ1, which lacks the
S5 Trp, or activate neuronal KCNQs even after their S5 Trp has
been substituted38. Conversely, it is interesting to note that reti-
gabine itself is a weak activator of GABA receptors39, perhaps a
further hint of similarities between the W265-based binding site
in KCNQ3 and the GABA-binding site of canonical GABAA
receptors. It will be of interest to determine whether cnidarian
KCNQs bearing the S5 W are also sensitive to GABA, and to
compare their expression pattern to that of non-W cnidarian
KCNQs.
Our principal ﬁnding, that M-channels are novel, unexpected
targets for GABA, with sensitivity comparable to canonical
GABAARs in vertebrate CNS, changes current understanding of
the potential mechanisms underlying GABA-mediated inhibition,
which up until now was considered to involve solely GABAA, B, C
receptors. The EC50 we observe for KCNQ2/3-dependent cellular
hyperpolarization of 120 nM GABA (Fig. 2h), is similar both to
the Kd we observe for 3H-GABA binding to KCNQ3 (Fig. 1j), and
to the tonic level of GABA (160 nM), consistent with KCNQ2/3
channels directly binding GABA to inﬂuence neuronal membrane
potentials at rest. Our ﬁndings, together with the known ability of
KCNQ2/3 to regulate GABA release8, 9, and strong expression
overlap of KCNQ2/3 with GABAergic neurons7, suggest the
potential for an underlying feedback mechanism.
Additionally, our results demonstrate that KCNQ2/3 has the
capacity to act as a chemosensor of the extracellular neuro-
transmitter/metabolite landscape, which could enable M-channels
to respond to the balance of these molecules and by doing so
regulate cellular excitability over time. Metabolic shifts favoring
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increased extracellular GABOB over GABA would be predicted,
based on our data, to favor cellular excitability, as GABOB could
compete out GABA from KCNQ3-W265, resulting in a positive
shift in the voltage dependence of M-current activation compared
to if GABA were bound (as in Fig. 6d). It is also interesting to
speculate a role for BHB activation of KCNQ2/3 channels in the
anticonvulsant effects of the ketogenic diet, given that BHB is the
ﬁrst ketone body produced during fasting or ketogenic diets, and
also in diabetic ketoacidosis. However, all these ideas require
further testing in native brain tissue preparations before any ﬁrm
conclusions can be drawn as to the precise physiological roles of
M-current GABA sensitivity. Finally, as GABA and analogs, in
particular GABOB (EC50 of 0.12 µM), activate KCNQ2/3 chan-
nels with a greater potency (albeit lower efﬁcacy) than retigabine
and analogs, the new ﬁndings could point the way to alternative
chemical spaces for therapeutic neuronal KCNQ activation.
Methods
Channel subunit cRNA preparation and oocyte injection. cRNA transcripts
encoding human KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNA1, or
KCNE1 were generated by in vitro transcription using the T7 polymerase
mMessage mMachine kit (Thermo Fisher Scientiﬁc), after vector linearization,
from complementary DNA (cDNA) sub-cloned into plasmids incorporating
Xenopus laevis β-globin 5′ and 3′ untranslated regions ﬂanking the coding region
to enhance translation and cRNA stability. cRNA was quantiﬁed by spectro-
photometry. Mutant KCNQ3 cDNAs were generated by site-directed mutagenesis
using a QuikChange kit according to manufacturer’s protocol (Stratagene, San
Diego, CA) and corresponding cRNAs prepared as above. Defolliculated stage V
and VI Xenopus laevis oocytes (Ecocyte Bioscience, Austin, TX) were injected with
Kv channel α subunit cRNAs (5–10 ng). Oocytes were incubated at 16 °C in Barth’s
saline solution (Ecocyte) containing penicillin and streptomycin, with daily
washing, for 3–5 days prior to TEVC recording or 3H-GABA binding assays.
Radioligand binding assays. Each group of oocytes was placed in a round-bot-
tomed, 10-ml culture tube, washed with ND96, and then resuspended in ND96
containing 100 nM γ-[2,3-3H(N)]-aminobutyric acid (3H-GABA) (Perkin Elmer,
Waltham, MA) at 25–40 Ci/mmol speciﬁc activity, for a 30 min incubation at room
temperature. Oocytes were then washed four times in 16 °C ND96, then transferred
to individual wells in a 96-well plate and lysed in 0.2% SDS in ND96. Each oocyte
lysate was transferred to a scintillation vial containing 5 ml cytoscint scintillation
cocktail ﬂuid (MP Biomedicals, Santa Ana, CA). Vials were capped, shaken, and
then allowed to sit at room temperature for at least 30 min before scintillation
counting in a Beckmann Coulter LS6500 liquid scintillation counter. Counts per
minute were normalized to channel protein surface expression, which was
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H-bonding with L237 in the S4–5 linker. d, e GABOB (d), but not glutamate (e), antagonizes the effects of GABA on KCNQ2/3 activation in oocytes
(n= 4–6). Upper, mean tail currents; lower, current fold-change elicited by neurotransmitter combination versus voltage. f GABOB antagonizes
the effects of retigabine on KCNQ2/3 activation in oocytes (n= 10). Upper, mean tail currents; lower, current fold-change elicited versus voltage. Data are
for KCNQ2/3 in the absence of retigabine (Ctrl), with retigabine (RTG), or with retigabine+GABOB
(RTG+GABOB). **P < 0.01; ****P < 0.0001
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quantiﬁed using a surface biotinylation approach similar to previously described
for oocyte membrane proteins40 as follows: in parallel experiments to the binding
assays, at 5 days post-cRNA injection, Xenopus oocytes (5 per group) expressing
KCNQ1, 2, 3, 4 or 5, and water-injected controls, were washed with ND96, and
gently agitated for 1 h at 4 °C in sulfo-NHS-SS-biotin (Pierce) (0.5 mg/ml in
ND96). Oocytes were next washed in 5 ml per group quenching solution (192 mM
glycine, 25 mM Tris-HCl, pH 7.4) for 10 min to quench unreacted biotin. Oocytes
were next incubated in 1 ml per group homogenization buffer (in mM, 150 NaCl, 2
CaCl2, 20 Tris, 2% Nonidet P-40) with 2% protease inhibitor cocktail (Pierce) and
then lysed with a 20 ml pipette tip, vortexed, centrifuged at 4000 r.p.m. (10 min, 4 °
C). The supernatant was mixed in Eppendorf tubes end-over-end overnight at 4 °C
with high-capacity streptavidin agarose beads (Thermo Fisher, Huntington Beach,
CA) (20 µl per group). The beads were gently centrifuged to precipitate surface-
biotinylated membrane proteins that were bound to the avidin-coated beads,
washed four times in homogenization buffer, resuspended in SDS-PAGE loading
buffer containing 5% dithiothreitol, heated to 70 °C for 10 min with intermittent
vortexing, and then separated on 4–12% ClearPage TEO-Tricine gradient gels (CBS
Scientiﬁc, San Diego, CA). Gels were stained for 20 min in Coomassie Brilliant Blue
G-250 (Sigma) in methanol/acetic acid, then destained for several hours in
methanol/acetic acid. Coomassie blue was used, as its staining versus protein
concentration is linear over a wide protein concentration range, membrane pro-
teins are relatively scarce in non-injected oocyte membranes, and this approach
avoids epitope tagging the different KCNQs, which could lead to other artifacts
such as altered GABA binding or surface expression. There was one prominent
protein band in the gel lanes of KCNQ-expressing groups, and a similar but much
fainter band in non-injected oocytes (perhaps corresponding to endogenous
Xenopus KCNQ141). Band densities were quantiﬁed using ImageJ (NIH, Bethesda,
MD), averaged for four groups of ﬁve oocytes each, and then binding assay 3H-
GABA CPM were normalized to mean band density to correct for the different
surface expression of the different KCNQ isoforms. This correction did not qua-
litatively alter the pattern of results, which in either corrected or non-corrected
datasets showed a clear distinction between binding in water or KCNQ1-cRNA-
injected oocytes versus the much higher binding in oocytes expressing KCNQ2–5
(Supplementary Fig. 1).
For the binding competition assay, the control group was treated as before. The
competition group was placed in a round-bottomed, 10-ml culture tube, washed
with ND96 containing 1 mM cold γ-aminobutyric acid (Sigma, Carlsbad, CA) and
resuspended in ND96 containing 100 nM γ-[2,3-3H(N)]-aminobutyric acid and 1
mM cold GABA (Sigma), and incubated for 30 min at room temperature. The
competition group was then washed four times in 16 °C ND96 containing 1 mM γ-
aminobutyric acid, then transferred to individual wells in a 96-well plate and lysed
in 0.2% SDS in ND96. Each oocyte lysate was transferred to a scintillation vial
containing 5 ml cytoscint scintillation cocktail ﬂuid (MP Biomedicals). Vials were
capped, shaken, and then allowed to sit at room temperature for at least 30min
before scintillation counting in a Beckmann Coulter LS6500 liquid scintillation
counter. For the saturation binding assays, a similar approach was taken but a range
of ten different γ-[2,3-3H(N)]-aminobutyric acid concentrations were employed
(0.1–1000 nM), with versus without 1 mM cold GABA. The groups with cold GABA
in addition to γ-[2,3-3H(N)]-aminobutyric acid were used to calculate non-speciﬁc
binding, and subtracted from total binding to give speciﬁc binding. CPM were
converted to fmol/oocyte after correcting for counter efﬁciency. Bmax and Kd values
were calculated using automated nonlinear regression analysis in GraphPad prism.
Two-electrode voltage clamp. TEVC recording was performed at room tem-
perature with an OC-725C ampliﬁer (Warner Instruments, Hamden, CT) and
pClamp8 software (Molecular Devices, Sunnyvale, CA) 3–5 days after cRNA
injection as described in section above. Oocytes were placed in a small-volume
oocyte bath (Warner) and viewed with a dissection microscope. Chemicals were
sourced from Sigma. Bath solution was (in mM): 96 NaCl, 4 KCl, 1 MgCl2, 1 CaCl2,
10 HEPES (pH 7.6). GABA and GABOB were stored at −80 °C as 1M stocks in
molecular grade H2O and diluted to working concentrations on each experimental
day. Valeric acid was stored as a 5 mM stock in Ringer’s solution at 4 °C and
diluted to working concentrations each experimental day. β-hydroxybutyric acid
was stored at 4 °C as a 480 mM stock in 100% ethanol and diluted to working
concentrations each experimental day. All compounds were introduced to the
recording bath via gravity perfusion at a constant ﬂow of 1 ml per min for 3 min
prior to recording. Pipettes were of 1–2MΩ resistance when ﬁlled with 3 M KCl.
Currents were recorded in response to pulses between −80 mV and +40 mV at 20
mV intervals, or a single pulse to +40 mV, from a holding potential of −80 mV, to
yield current-voltage relationships, current magnitude, and for quantifying acti-
vation rate. Deactivation was recorded at −80 mV after a single activating pulse to
+40 mV, from a holding potential of −80 mV. For wortmannin studies, oocytes
were incubated in 30 µM wortmannin for 3 h at 16 °C prior to recording. TEVC
data analysis was performed with Clampﬁt (Molecular Devices) and Graphpad
Prism software (GraphPad, San Diego, CA, USA); values are stated as mean ± SEM.
Normalized tail currents were plotted versus prepulse voltage and ﬁtted with a
single Boltzmann function:
g ¼ ðA1  A2Þ
1þ exp V 1
2
 V
 
=VS
h in o
þ A2
; ð1Þ
where g is the normalized tail conductance, A1 is the initial value at −∞, A2 is the
ﬁnal value at +∞, V1/2 is the half-maximal voltage of activation, and VS the slope
factor. Activation and deactivation kinetics were ﬁtted with single exponential
functions.
Whole-cell patch clamp electrophysiology. CHO cells (ATCC) were seeded on
poly-L-lysine-treated glass coverslips in 24-well plates and transfected the next day
using 0.5 µg each of mouse KCNQ2 and KCNQ3 cDNA in a CMV vector per well
in normal media (DMEM with 10% FBS and 1% penicillin/streptomycin). The
transfection reagent used was TransIT-LT1 (Mirus Bio LLC, Madison, WI, USA)
and cells were patched 48–72 h post transfection. PC12 cells (Sigma) were grown in
a 95% O2/5% CO2 and humidiﬁed environment at 37 °C in RPMI 1640 medium
supplemented with 10% heat inactivated horse serum, 5% fetal bovine serum, and
1% penicillin/streptomycin. Media was replenished every 3 days and cultures were
split once a week. For differentiation, cells were plated on 13 mm plastic coverslips,
pre-treated with poly-L-lysine and collagen, in RPMI 1640 medium supplemented
with 1% horse serum and 50 ng/ml nerve growth factor (NGF) and cultured for up
to 7 days. Neurite outgrowth was observed from days 3–4 of differentiation and
cells were used for experiments from 5 days post differentiation. Cell culture plastic
ware and reagents were purchased from VWR and Fisher Scientiﬁc unless other-
wise stated.
For both CHO cells and PC12 cells, currents were recorded in whole-cell mode
at room temperature (22–25 °C) with 3–6MΩ borosilicate glass electrodes
backﬁlled with solution containing (in mM): 90 K acetate, 20 KCl, 40 HEPES, 3
MgCl2, 1 CaCl2, 3 EGTA-KOH, 2 MgATP; pH 7.2. Cells were continuously
perfused at 1–2 ml/min with extracellular solution (ECS) containing (in mM): 135
NaCl, 5 KCl, 5 HEPES, 1.2 MgCl2, 2.5 CaCl2, 10 glucose; pH 7.4. Drugs were added
to the ECS where indicated, as follows: 100 µM picrotoxin, 10 µM CGP55845, 10
µM XE991, and 100 µM GABA. All chemicals were purchased from Fisher
Scientiﬁc or Sigma-Millipore.
Cells were held at −80 mV in voltage clamp before applying the voltage step
protocols and currents were recorded, in response to pulses between −80 mV and
+40 or +60 mV at 20 mV intervals followed by a single pulse to −30 mV, using a
CV −7A Headstage (Axon Instruments, Foster City, CA, USA). Currents were
ampliﬁed using a Multi-clamp 700B (Axon Instruments), low-pass ﬁltered at 2–10
kHz using an eight-pole Bessel ﬁlter and digitization was achieved (sampling at
10–40 kHz) through a DigiData 1322A interface (Molecular Devices). The
pClamp8 (Molecular Devices) software package was used for data acquisition and
Clampﬁt was used for analysis, along with Graphpad Prism 7.0 (Graphpad).
Normalized tail currents were plotted versus prepulse voltage and ﬁtted with a
single Boltzmann function.
Neuronal isolation and recordings. Adult male mice were purchased from
Jackson Labs and then housed and used according to a protocol approved by the
Institutional Animal Care and Use Committee of University of California, Irvine,
and consistent with recommendations in the NIH Guide for the Care and Use of
Laboratory Animals (8th edition, 2011). To analyze the effects of GABA on native
neuronal M-current, DRG were isolated from adult male mice (2–4 months of age),
and dissociated using collagenase and trypsin. DRG neurons were then cultured on
poly-L-lysine and laminin-coated plastic coverslips in RPMI 1640 with 10% horse
serum and 1% penicillin/streptomycin at 37 °C for 1–4 days before electro-
physiological recordings were performed using perforated patch clamp. Ampho-
tericin B (VWR, Radnor, PA) was dissolved in DMSO at 5 mg/ml (stock solution),
then diluted to 150–200 µg/ml in intracellular solution and sonicated with a probe
sonicator on ice for 5 s, kept at room temperature in the dark, and replaced every
hour with a fresh solution from the stock. The working amphotericin solution was
backﬁlled into borosilicate glass electrodes (3–5MΩ) previously tip-ﬁlled to ~0.5
mm with intracellular solution lacking amphotericin B, immediately prior to
sealing onto individual neurons. After whole-cell conﬁguration was achieved and
capacitance stabilized, whole-cell recordings were performed essentially as descri-
bed in the prior paragraph, with the following differences: neurons were held at
−20 mV to inactivate other channels before the test pulses; ofﬂine leak subtraction
was performed.
Sequence analysis and modeling. Chemical structures and electrostatic surface
potentials (range, −0.1 to 0.1) were plotted using Jmol, an open-source Java viewer
for chemical structures in 3D: http://jmol.org/. For docking, the X. laevis KCNQ1
cryoEM structure42 was ﬁrst altered to incorporate KCNQ3/KCNQ5 residues
known to be important for retigabine and ML-213 binding, and their immediate
neighbors, followed by energy minimization using the GROMOS 43B1 force
ﬁeld43, in DeepView44. Thus, X. laevis KCNQ1 amino acid sequence LITTLYIGF
was converted to LITAWYIGF, the underlined W being W265 in human KCNQ3/
KCNQ5 and the italicized residues being the immediate neighbors in KCNQ3/
KCNQ5. In addition, X. laevis KCNQ1 sequence WWGVVTVTTIGYGD was
converted to WWGLITLATIGYGD, the underlined L being Leu314 in human
KCNQ3/KCNQ5 and the italicized residues being the immediate neighbors in
KCNQ5 and/or KCNQ3. Surrounding non-mutated sequences are shown to
illustrate the otherwise high sequence identity in these stretches. Unguided docking
of GABA, retigabine, and ML-213, to predict native binding sites, was performed
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using SwissDock45 with CHARMM forceﬁelds46. Phylogenetic analysis was per-
formed using BLAST searching47 of predicted or known protein sequences from
multiple genomes (where available) from each clade; KCNQ5 sequences for
representative organisms from each clade are shown. Genomes were accessed using
the US National Center for Biotechnology Information (NCBI), Joint Genome
Institute (JGI), Kyoto Encyclopedia of Genes and Genomes (KEGG), UCSC
Genome Browser Gateway, and the Elephant Shark Genome Project. Species names
for the exemplars shown in Fig. 1a are as follows: Human, Homo sapiens; Frog,
Xenopus tropicalis; Carp, Cyprinus carpio; Shark, Callorhincus milii; Lamprey,
Petromyzon marinus; Acorn worm, Sacclogossus kowalevskii; Bat star, Patiria
miniata; Snail, Biomphalaria glabrata; Fly, Musca domestica; Leech, Helobdella
robusta; Tapeworm, Hymenolepsis microstoma; Nematode, Caenorhabditis elegans;
Hydrozoa, Hydra vulgaris; Anthozoa, Nematostella vectensis.
Statistical analysis. All values are expressed as mean ± SEM. One-way analysis of
variance (ANOVA) was applied for all tests; if multiple comparisons were per-
formed, a post-hoc Tukey’s HSD test was performed following ANOVA. All P-
values were two-directional. Statistical signiﬁcance was deﬁned as P < 0.05.
Data availability. The datasets generated during the current study are available
from the corresponding author on reasonable request.
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